Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Drug Profile

Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Alternative Names: second generation TCR therapeutics - Kite Pharma/bluebird bio

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator bluebird bio; Kite Pharma
  • Developer Kite Pharma
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Jun 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top